Contract manufacturer FujiFilm Diosynth Biotechnologies, which has been expanding its footprint in Holly Springs, has signed a $3 billion agreement to make treatments for Regeneron Pharmaceuticals. Under the agreement,

FUJIFILM Diosynth Biotechnologies, a global contract development and manufacturing organization (CDMO) with major operations in North Carolina, has signed an agreement valued at over $3 billion to produce biologic medicines for Regeneron Pharmaceuticals.

Ahead of its scheduled opening later this year, the massive Fujifilm Diosynth Biotechnologies manufacturing plant in Holly Springs has added a new customer in a lucrative deal. On Tuesday, Fujifilm Diosynth announced a 10-year agreement worth more than $3 billion to make medicines for the New York drugmaker Regeneron in the Triangle.